Eylea is given by a doctor or nurse and billed by the clinic, not a pharmacy. Your care team and your insurance decide which product you get, so ask them what you’d pay.

How do you pay?

How to pay the least

Given by your care team

Billed by the clinic

Eylea is given by a doctor or nurse, not picked up at a pharmacy.

  1. Ask your care team or your plan what you’d pay before your visit.

Compare every option

Question
Brand nameEylea
Authorized genericaflibercept
Regular genericaflibercept
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Not soldAsk the pharmacy
Same as Eylea?
The original
–
–

Brand nameThe maker’s card

EYLEA4U Commercial Copay Card Program

Savings card from Regeneron

No insuranceNeeds insuranceNo cash price listed.
Insurance · as little as $0 a treatment

The card takes up to $20,000 a year off your co-pay.

Sign up on eylea.us 

Or call 1-855-395-3248.

In the maker’s words

“Eligible patients with commercial insurance may pay as little as a $0 copay for each EYLEA treatment with the EYLEA Commercial Copay Card.”

From the maker’s offer on eylea.us, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Authorized genericNot sold

There isn’t one. An authorized generic is Eylea itself, from the same company, sold without the brand name, and usually for less. For now Eylea is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

Eylea is a biologic. Biologics don’t have generics, but some have biosimilars or an unbranded version from the same maker. Ask your pharmacist or prescriber whether one is sold. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

EYLEA is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of patients with:

  • Neovascular (Wet) Age-Related Macular Degeneration (AMD)
  • Macular Edema Following Retinal Vein Occlusion (RVO)
  • Diabetic Macular Edema (DME)
  • Diabetic Retinopathy (DR)
  • Retinopathy of Prematurity (ROP)

Source: the FDA label for Eylea (Regeneron Pharmaceuticals, Inc.), July 7, 2026. Full label on DailyMed 

Good to know